DouglasMichaelSprouleMD

Child Neurology • New York, NY

Assistant Professor of Neurology, Columbia University Medical Center

Join to view full profile

Dr. Sproule is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sproule's full profile

Already have an account?

Office
180 Fort Washington Ave
Fl 5
New York, NY 10032
Phone+1 212-342-3679

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2005 - 2008
New York Presbyterian Hospital (Columbia Campus)Residency, Child Neurology, 2003 - 2006
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 2003 - 2005
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

Certifications & Licensure

NY State Medical License 2005 - 2027
MA State Medical License 2013 - 2014
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Clinical Trials

Clinical Study of Spinal Muscular Atrophy Start of enrollment: 2005 May 01
Completed
Giant Axonal Neuropathy Natural History Study Start of enrollment: 2011 Dec 01
Terminated

Publications & Presentations

PubMed

51 citations
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
Gretchen Thomsen, Arthur H.M. Burghes, Caroline Hsieh, Janet Do, Binh T. T. Chu
Nature Medicine. 2021-10-01
210 citations
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, ...
John W. Day, Richard S. Finkel, Claudia A. Chiriboga, Anne M. Connolly, Thomas O. Crawford
The Lancet. Neurology. 2021-04-01
29 citations
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for ...
Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru
Journal of Market Access & Health Policy. 2021-02-28

Press Mentions

BridgeBio Pharma to Present Preliminary Findings on Its Novel Bioassay Measuring Glycosylated Alpha-Dystroglycan (⍺DG) in Patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)March 17th, 2023
BridgeBio Pharma (BBIO) Reports 12-Month Results from Phase 2 Study of BBP-418October 14th, 2022
Dosing Begins in Phase 2 Trial Testing Oral Therapy BBP-418 for LGMD2iMarch 2nd, 2021
Join now to see all